LLY

SELL

Eli Lilly and Company

Healthcare · Rank #128 · Analyzed Apr 20, 2026

$927.03

Current Price

$717.46

Intrinsic Value

+0.6%

Upside/Downside

4/10

Score

4/5

Quality

Analysis Summary

Valuation Consensus0/3 methods agree

Quality Score4/5.0

Framework RatingSELL

Price vs Intrinsic ValueUndervalued by 0.6%

Fair Value Range

Low$23.76

Base (IV)$717.46

High$932.70

Entry Points

Conservative$23.76

Moderate$370.61

Aggressive$717.46

Quality & Moat Breakdown

Return on Equity101.2% → 1.0/1.0

Debt LevelD/E 165 → 0/1.0

Revenue QualityGrowth 31.3%, margin Δ+54.7% +recovery → 1.0/1.0

Moat Strength4.0/5 → 1.0/1.0

Profit Margins31.7% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods — Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation — with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.